DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of... The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.
- Mechanism
- Curator reviewed
DDP225 is an orally-active compound that targets two key pathways that control the gastrointestinal (GI) system, thus giving it the potential to address multiple symptoms associated with IBS-d. DDP225 has a dual mechanism of action. It possesses both noradrenaline reuptake inhibition and 5-HT3 receptor antagonist properties.
- Primary indication
- Investigated for use/treatment in alzheimer's disease, depression, diarrhea, gastrointestinal diseases and disorders (miscellaneous), and irritable bowel syndrome (IBS).Curator reviewed
- Formula / weight
- C17H20ClFN4OS · 382.88 g/mol (avg)
- Code names
- DDP-225 · MCI-225
Resolves to
SAURKKOJWIFYSR-UHFFFAOYSA-NSMILESO.Cl.CC1=CC2=C(N=C(N=C2S1)N1CCNCC1)C1=CC=CC=C1FWhat you can answer from here — as of June 12, 2020
Which drugs share a target with DDP-225, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account